Hendra virus (HeV) is one of the two prototypical members of the Henipavirus genus of paramyxoviruses, which are designated biosafety level 4 (BSL-4) organisms due to the high mortality rate of Nipah virus (NiV) and HeV in humans. Paramyxovirus cell entry is mediated by the fusion protein, F, in response to binding of a host receptor by the attachment protein. During posttranslational processing, the fusion peptide of F is released and, upon receptor-induced triggering, inserts into the host cell membrane. As F undergoes a dramatic refolding from its prefusion to postfusion conformation, the fusion peptide brings the host and viral membranes together, allowing entry of the viral RNA. Here, we present the crystal structure of the prefusion form of the HeV F ectodomain. The structure shows very high similarity to the structure of prefusion parainfluenza virus 5 (PIV5) F, with the main structural differences in the membrane distal apical loops and the fusion peptide cleavage loop. Functional assays of mutants show that the apical loop can tolerate perturbation in length and surface residues without loss of function, except for residues involved in the stability and conservation of the F protein fold. Structure-based disulfide mutants were designed to anchor the fusion peptide to conformationally invariant residues of the F head. Two mutants were identified that inhibit F-mediated fusion by stabilizing F in its prefusion conformation.
paramyxovirus F protein | F-protein atomic structure | metastable F-protein stabilization | Hendra virus | membrane fusion T he Paramyxoviridae family of viruses includes many species known to cause human and animal disease, including Nipah virus (NiV) and Hendra virus (HeV) of the genus Henipavirus (1). This emergent genus was first described in 1994 with a disease outbreak of HeV, followed by a disease outbreak of NiV in 1999 (2) , and was recently expanded by the discovery of the Cedar virus (3) and evidence for 19 new species of African henipaviruses (4) . Both NiV and HeV have caused outbreaks of encephalitic and respiratory illness in humans in Malaysia, Bangladesh, Australia, and several neighboring countries, with high morbidity and mortality, and are designated biosafety level 4 (BSL-4) organisms (5, 6) . The animal reservoir for NiV and HeV is Pteropus spp. fruit bats. These viruses are transmitted to humans from an intermediate animal vector, pigs in the case of NiV and horses in the case of HeV. Serological and genetic evidence for henipaviruses has been discovered in Pteropus far from known locations of disease incidence (6) .
Like other paramyxoviruses, the henipaviruses are enveloped viruses that are densely studded on their outer surfaces with the two transmembrane-anchored glycoproteins involved in entry of the virion into host cells via membrane fusion (7) . These glycoproteins are the fusion glycoprotein, F, which mediates fusion of the viral lipid envelope with the host cell plasma membrane, and the attachment glycoprotein, G, in henipaviruses, which acts as a trigger for fusion upon specific recognition of the host cell receptors ephrinB2 and ephrinB3 (8, 9) . Triggering is thought to occur via sequential conformational changes in G that are communicated to F while they associate in F-G complexes (10, 11) . Exposure of stalk residues in G, which are thought to be occluded by its receptor-binding head domains before triggering, appear key to initiating F refolding and membrane fusion.
The trimeric F protein in its prefusion form has a globular conformation consisting of three domains (DI, DII, and DIII), followed by a C-terminal stalk, transmembrane domain, and cytoplasmic tail (12) . DI and the Ig-like fold DII are implicated in interactions with the attachment protein (13, 14) . F also contains two heptad repeats, HRA in DIII and HRB in the stalk. During posttranslational processing, the F 0 precursor is cleaved by the cellular protease cathepsin L at a defined site following a basic residue, K109 in HeV F, resulting in release of the fusion peptide segment located C-terminal to the cleavage site. Cleavage results in two disulfide-linked fragments, F 1 and F 2 (15, 16) . Upon activation, the F protein undergoes large-scale refolding, mostly in DIII. HRA is extended into a long α-helix, which forms a six-helix bundle with the HRB region of the stalk. This refolded F forms a golf teeshaped postfusion conformation (17) , which is modeled to bring the host and virus membranes together as the fusion peptides inserted into the host-membrane oligomerize with the virionembedded portion of the HRB stalk (12) .
The atomic resolution structures of the prefusion forms of the F protein have been solved for two paramyxoviruses, parainfluenza virus 5 (PIV5) and respiratory syncytial virus (RSV) (12, 18) . These two proteins exhibit fairly low sequence identity and significant differences in their structures, although several key domain features are conserved (18) . HeV F shares low sequence similarity with PIV5 and lower sequence similarity with RSV (27.9% and 21.3% identity, respectively, calculated with Significance Hendra virus (HeV) is a deadly member of the Henipavirus genus of paramyxoviruses, which causes high mortality in humans and horses. We determined the crystal structure of the HeV fusion protein, F, in its metastable, prefusion conformation. The structure is highly conserved compared with parainfluenza virus 5 (PIV5) F, but divergent from respiratory syncytial virus (RSV) F. The structural similarities suggest a common mode of activation for PIV5 and HeV F despite low sequence homology. Structural differences in the HeV F cleavage/activation loop are observed that may be explained by a requirement for cleavage by cathepsins. The HeV F structure was used to predict disulfide bonds that stabilize its prefusion conformation, providing a construct for vaccine and functional studies.
ClustalX). The fusion (F)-attachment (HN) protein pair of PIV5, along with the fusion-attachment protein pair of Newcastle disease virus and human parainfluenza virus type 3, behave according to the "association" model of fusion activation. Although interaction is required for fusion, the F-HN pairs of these proteins have relatively low affinity for each other and host receptor binding is thought to bring the proteins into greater association at initiation of fusion. The F protein of RSV does not require its cognate attachment protein for virus fusion and replication. In contrast, the fusion-attachment protein pairs of the Morbillivirus genus (measles and canine distemper virus) and henipaviruses, NiV and HeV, behave more consistently with the "dissociation" model of fusion activation. Biochemical evidence suggests a relatively higher affinity for the fusion-attachment proteins and preassociation in complexes where dissociation only occurs upon receptor binding (8, 9, 19) . To date, no high-resolution structural information has been available for fusion proteins in the dissociation class.
Here, we present the crystal structure of the HeV F ectodomain. Its structure has a high degree of structural similarity to the structure of PIV5 F despite low sequence similarity. The areas of greatest structural deviation are at the pair of loops at the apical region of the trimer and at the fusion peptide cleavage site. Sitedirected mutagenesis within the apical loops showed that residues that have a role in maintaining tertiary structural integrity of the region have effects on fusion and cell surface expression. Based on the crystal structure, amino acid pairs with a likelihood of forming disulfide bonds were predicted computationally. Double-Cys mutants of HeV F were generated with the intent of preventing refolding of the HRA region that is crucial for fusion. Two of the mutants show loss of fusion activity, while being expressed at the cell surface and recognized by a mAb (5B3) specific for the prefusion conformational state.
Results and Discussion
Overall Structure of HeV F Is Similar to PIV5 F. The HeV F ectodomain consisting of residues 26-482 fused to the GCN4 trimerization domain (12) was expressed in 293F cells and crystallized. X-ray diffraction data were collected to 3.2 Å, and a molecular replacement solution was found with the PIV5 prefusion F ectodomain (12) as a search model ( Fig. S1 A-C and Table S1 ). The crystal structure of the HeV F ectodomain ( Fig. 1 A-C) shows a high degree of structural conservation with the crystal structure of PIV5 F. In addition to high similarity between the folds of DI, DII, and DIII ( Fig. 1B and Fig. S1 ), relative domain orientations are similar, resulting in an rmsd by secondary structure matching (SSM) of 2.27 Å between the ectodomains of HeV F and PIV5 F (Fig. 1C) . Although conserved fold elements exist between the individual domains of RSV F (18) and HeV F (Fig. 1D) , the overall correspondence of the structures is much poorer. In contrast to PIV5 F, significant differences in relative domain orientations exist between all three domains of the globular head between HeV F and RSV F (Fig. S1C ). These differences are expressed as rotation of a domain about an axis following SSM superposition of a fixed domain, calculated with DynDom (20) . The positions of DII in HeV F and RSV F relative to DI differ by 43°, and the positions of DIII relative to DI differ by 64° (Fig. 1E) , resulting in an rmsd of 5.11 Å between the RSV and HeV F structures.
N-linked carbohydrate residues were observed for all of the previously reported glycosylation sites of HeV F, N67, N99, N414, and N464 (21) (Fig. 1C) . N67 is on the N-terminal apical loop, and N99 is at the base of the fusion peptide cleavage site loop. The only N-glycan site location conserved between HeV F and PIV5 is HeV N464, which coincides with PIV5 457 on the HRB stalk. Notably, there is no functional conservation between the sites, because HeV F N464 is dispensable for fusion and processing (21) , whereas the stalk glycan of PIV5 is essential for stability, cell surface expression, and proteolytic processing (22) . The only HeV F glycan necessary for F expression and function, N414 (21) , is in DII on the lower extremity of the globular head.
Investigation of Apical Loop Differences in HeV F. A notable difference between the HeV F and PIV5 F structures occurs in the pair of loops at the topmost surface of the trimer. Compared with the PIV5 loops, the HeV F loops are more oriented toward the central axis and have more of an α-helical than β-sheet secondary structure ( Fig. 2 A and B) and the N-terminal loop is shorter by one amino acid (Fig. 2C ). These differences result in a slight overall compaction in structure in the apical region. V68 has a role in structural stabilization of the double loops due to insertion of its side chain in a hydrophobic pocket that includes I179, L183, V184, and I187 from the second apical loop (Fig. 3A) . The disulfide bond between C71 and C185 joining the first and second apical loops is conserved with PIV 5. Both HeV and PIV5 F have N-linked glycans on the N-terminal apical loop, but the N-linked glycan of HeV at N67 is N-terminal, whereas the N-linked glycan of PIV5 at N65 is C-terminal to the loop (Fig. 3A) .
Site-directed mutants were generated in the apical loop region of HeV F to assess the contribution of individual residues to fusion function (Fig. 3A) , because these residues could represent structural differences associated with G interaction and/or activation. Single Ala insertions were made following residues 65, 68, and 70 (mutants 65B, 68B, and 70B) to mimic the longer PIV5 loop and to test if loop length has an impact on HeV F function. Ala mutants were made of the polar surface residues K70 and D185 and the aliphatic buried residue V68. Residue T164 was mutated to Leu because it is 
Of the site-directed mutants, only V68A, T164L, and 65B (an insertion mutant), listed in order of increasing defect, show significant effects on fusion (Fig. 3B and Fig. S2 ). Mutant V68A shows reduced cell surface protein expression, which would contribute, at least partially, to its decreased fusogenicity (Fig. S3 and Table S2 ), but the mutation may also affect the stability of the prefusion conformation. Mutant T164L has robust total protein expression but undergoes abnormal proteolysis, resulting in a smaller F 1 fragment, which is a likely contributor to its decreased cell surface expression and fusogenicity (Fig. S3) . Mutant 65B has normal proteolytic processing, a mild decrease in total expression level, and a more significant decrease in cell surface expression to ∼25% of WT, but it shows negligible fusion activity ( Fig. S3 and Table S2 ). Therefore, Ala insertion after residue 65 affects fusion activity more severely than cell surface expression.
Based on the fusion and protein expression assays, we conclude that the protein surface residues K70 and D188 alone are unlikely to be crucial residues involved in HeV F interaction with potential binding partners. The one-residue-length decrease of the first apical loop in HeV F is not crucial for function, because only 65B of the three loop insertion mutants resulted in a fusion level or protein processing defect ( Fig. 3B and Fig. S3 ). The 68B insertion has the additional effect of disrupting the N-X-S glycosylation motif beginning at residue N67, resulting in an F 0 fragment with decreased molecular weight relative to WT (Fig. S3) , showing that this region is tolerant of various types of perturbations. The common feature of V68A and 65B, the two mutants that disrupt total fusion activity, and the amount of cell surface expression is that they could disrupt the secondary structure of the apical loop region. V65 of HeV F is in a strand that is structurally conserved with PIV5 just before it begins to diverge in the apical loop region, and 65B may disrupt a conserved feature that is important for the function of F. The hydrophobic packing of the two apical loops by V68 may substitute for the β-sheet interactions between the loops in PIV5. Maintaining these contacts may be necessary to avoid trafficking defects or the early protein degradation that may lead to the decreased amount of V68 and 65B mutant proteins on the cell surface.
HeV F Fusion Peptide Cleavage Site Region. Residues 100-116 of HeV F, which surround the F 1 /F 2 cleavage site following residue K109, form an elongated, antiparallel β-sheet-like structure with the cleavage site at the turn. This structure is in contrast to residues 94-109 of PIV5, which form a circular, open loop (Fig. 4) . The residues C-terminal to the cleavage site in HeV F form a more defined β-strand structure. This strand makes β-sheet backbone interactions with a neighboring β-strand consisting of residues 425-428 from DII that is conserved between HeV F and PIV5 F (Fig. 4) .
These differences in fusion peptide conformation may reflect their recognition by different proteases during posttranslational processing. Unlike HeV F, which is cleaved by cathepsin L, PIV5 is cleaved into its fusion-active form by furin (23) . Crystal structures exist for furin in complex with peptide-derived synthetic inhibitors (24) and for cathepsin L in complex with a natural peptide substrate (25) , peptide-derived inhibitors (26) , and full-length protein inhibitors (27, 28) . The furin substratebinding pocket is well-suited to accommodate an open-loop conformation (Fig. S4A) . Its wide and rounded shape would force a linear peptide substrate to curve around to exit. The entirety of the binding pocket surface is electronegative, which is suitable for complementary electrostatic interactions with the poly-Arg preceding the cleavage site. In comparison to furin, the substrate-binding pocket of cathepsin L forms a longer and narrower groove (Fig. S4B) . The crystal structures of cathepsin L in complex with the MHC class II invariant chain p41 fragment and chagasin show that the turn of an elongated loop binds in the positions of the substrate-binding groove immediately preceding the cleavage site, whereas additional binding from the rest of the protein inhibitor is provided by insertion of two additional turns at separate points in the binding groove (Fig. S4C) . The elongated loop structure surrounding the cleavage site in HeV F suggests that it may insert into the cathepsin L active site in a similar fashion.
Prefusion HeV F Disulfide Bond Mutants. The crystal structure of the HeV F protein provides the opportunity to predict F variants that could be stabilized in the prefusion conformation, which would be useful for functional studies, antibody (Ab) epitope mapping, and vaccine antigen design. To stabilize prefusion F, double-Cys mutants were generated throughout the HRA region of HeV F with the intent of locking it in its prefusion conformation via disulfide bonds. Potential pairs of disulfide bondforming residues within the HeV F crystal structure were found with Disulfide by Design (29) , and six were chosen for further analysis (Fig. 5A ). All six mutants expressed to appreciable levels, but only two, Y97C-G131C and N100C-A119C, had normal proteolytic processing and were expressed at WT levels on the cell surface ( Fig. S3 and Table S2 ). The other four mutants had some combination of decreased or abnormal proteolytic processing and greatly decreased cell surface expression. All six mutants exhibited negligible fusion (Fig. 5B) . This result suggests that the Y97C-G131C and N100C-A119C mutants are locked in the prefusion conformation while on the cell surface and are unable to undergo the prefusion-to-postfusion conformational transition triggered by G. Although both residues are adjacent in the prefusion conformation, they end up on essentially opposite sides of the protein after fusion due to Y97 and N100 being on one side of the fusion peptide cleavage site and F131 and A119 on the other (Fig. 5A) . Residues N-terminal to the cleavage site are adjacent to the head in the postfusion conformation, whereas residues C-terminal to the cleavage site are embedded in the membrane at the base of the stalk (Fig. 5A) .
To confirm if the HeV F protein on the cell surface is in the prefusion conformation, HEK293T cells transfected with HeV F-expressing vector were analyzed by flow cytometry with an anti-HeV F mAb (5B3) specific for its prefusion conformation (30). The median fluorescence intensities (MFIs) (Fig. 5C, Fig. S5 , and Table S3) show that the Y97C-G131C and N100C-A119C mutants are present at the surface in the prefusion conformation at ∼60% of the WT level, consistent with the predicted disulfide bond stabilization. The radioimmunoprecipitation assay indicates that the total amount of HeV F on the cell surface may be similar to the total amount of HeV F of WT (Table S2) , potentially suggesting that a lower percentage of prefusion F accumulates for the disulfide bond mutants. However, variability in the radioimmunoprecipitation assay and in transfection efficiency, which could have an impact on the MFI, is too significant to determine the efficiency of folding of the disulfide bond mutants to the prefusion state. Nonetheless, the observed fusion defects in Y97C-G131C and N100C-A119C are much greater than the reduction in the amount of prefusion F at the cell surface detected by mAb 5B3 compared with WT. Therefore, we conclude that the majority of the decrease in fusion is most consistent with the F protein being locked in the prefusion conformation by disulfide bonds.
Engineering of vaccine antigens with introduced disulfide bonds has been explored as a means of generating more stable and/or more immunogenic variants (31, 32) . The metastability of viral fusion glycoproteins can be an obstacle for their expression, purification, and antigenicity due to their tendency to transition spontaneously from the prefusion to postfusion conformation (18, 33) . The successful engineering of disulfide bonds for maintaining fusion proteins in the prefusion conformation has been reported for measles, RSV, PIV5 F, influenza HA, and HIV gp120-gp41 trimers (32, (34) (35) (36) (37) . An additional benefit of prefusion-stabilizing disulfide bonds may be increased thermal stability during storage, because the WT prefusion-to-postfusion transition can be triggered by heat (38) . Disulfide bond-enhanced thermal stability and shelf life have been demonstrated in subunit vaccines for Lyme borreliosis (39) and ricin A toxin (40) . Our results with the HeV F Y97C-G131C and N100C-A119C mutants provide tools for further studies of HeV F fusion and antigenicity, as well as an additional example of how the engineering of disulfide bonds into metastable fusion proteins can be used to control their conformational and functional properties.
Conclusions
The HeV F ectodomain has a structure very similar to the structure of PIV5 F, suggesting that the mechanism for receptordependent triggering of fusion is conserved. However, HeV F preassociates with its attachment protein, G, before receptor binding, whereas PIV5 F does not. Significant structural differences are observed in their fusion peptide regions and the double apical loops. The more narrow and elongated loop of HeV F surrounding the K109 cleavage site likely reflects differences in the recognition site of its specific activating protease, cathepsin L, as opposed to furin, which is used by PIV5. The functional role of the double apical loops appears limited to its structural integrity based on our functional studies. Residues in these loops involved in structure stabilization and conservation are important for maintaining protein expression and function. Other residues within the F trimer must promote the preferential assembly of HeV into prefusion complexes with G, in contrast to PIV5 F, and these residues have yet to be identified. However, the overall structural conservation is consistent with a similar mode of F activation for Henipavirus and parainfluenza viruses. We have generated two HeV F disulfide mutants that fold to the prefusion form, while blocking F fusion activity. Both disulfide mutants generate covalent links between residues immediately preceding and following the fusion peptide cleavage site, so that they are unable to move apart in the conformational transition to the postfusion state. Fusion peptide immobilization via the structurebased introduction of such disulfide bonds provides a promising route for design of other stabilized viral fusion protein variants.
Materials and Methods
Protein Expression and Purification. The HeV F ectodomain (F ecto ) was expressed in HEK293F cells transiently transfected with the HeV F ecto -pCAGGS3 plasmid according to the high-density method of Backliwal et al. (41) . Cell culture medium was collected 5 d after transfection and dialyzed against 25 mM sodium phosphate (pH 7.6), 200 mM NaCl, and 10 mM imidazole. HeV F was purified from the medium by nickel-nitrilotriacetic acid (Ni-NTA) chromatography and eluted with a stepwise imidazole gradient. The peak fractions were further purified by size exclusion on a Superdex S200 (GE Healthcare Life Sciences) column in 25 mM Tris (pH 8.0), 200 mM NaCl, and 100 mM imidazole buffer.
Crystallization and Structure Solution of HeV F ecto . The His 8-tag was removed from HeV F ecto before crystallization by digestion with Factor XA (New England Biolabs) in 20 mM Tris (pH 7.4), 100 mM NaCl, and 2 mM CaCl 2 at a ratio of 1 μg of protease to 20 μg of F overnight at 4°C. Cleaved His-tags and uncleaved protein were removed by incubation with Ni-NTA beads, followed by removal of protease by size exclusion chromatography. HeV F ecto peak fractions were buffer-exchanged into 20 mM Tris (pH 8.0), 100 mM NaCl, and 1 mM EDTA, and then concentrated to 5 mg/mL for crystallization setup. Crystals were grown by vapor diffusion in a 1:1 protein/reservoir solution ratio at room temperature. The reservoir composition was 100 mM sodium acetate (pH 5. 
